Biogen Inc. (BIIB)Healthcare | Drug Manufacturers - General | Cambridge, United States | NasdaqGS
218.50 USD
-3.00
(-1.354%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 218.19 -0.31 (-0.310%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:34 a.m. EDT
Biogen presents a classic turnaround dilemma. While the forward P/E of 13x suggests the market expects a massive earnings recovery, the reality is stark: earnings have collapsed by 85% year-over-year, and the stock has lost over half its value over the past nine years. The long-term outlook remains fragile given the deteriorating Alzheimer's drug data and shrinking multiple sclerosis sales. However, short-term momentum is constructive, with the price trading above both the 50-day and 200-day averages and approaching its yearly high. Options activity highlights a defensive strategy, with heavy put buying at 190 acting as a floor while call buyers cluster near 220. Without a dividend to cushion the blow, investors are betting entirely on a fundamental pivot that hasn't happened yet. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.030719 |
| MSTL | 0.040776 |
| AutoETS | 0.041257 |
| AutoARIMA | 0.045745 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 56% |
| H-stat | 1.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.581 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 44.329 |
| Revenue per Share | 68.194 |
| Market Cap | 32,284,248,064 |
| Trailing P/E | 39.37 |
| Forward P/E | 13.21 |
| Beta | 0.16 |
| Profit Margins | 8.32% |
| Website | https://www.biogen.com |
As of Aug. 22, 2026, 4:34 a.m. EDT: Speculators are positioning for a range-bound outcome between 190 and 220, evidenced by the major option open interest walls at these strikes. Deep out-of-the-money calls and puts show inflated implied volatility, indicating a fear of significant tail risk despite the current price holding near its 52-week high. The flow suggests a defensive stance rather than a strong directional bet.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.56485 |
| Address1 | 225 Binney Street |
| All Time High | 480.18 |
| All Time Low | 0.354167 |
| Ask | 229.77 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 653,590 |
| Average Daily Volume3 Month | 1,128,030 |
| Average Volume | 1,128,030 |
| Average Volume10Days | 653,590 |
| Beta | 0.162 |
| Bid | 208.05 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 127.61 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 218.5 |
| Current Ratio | 1.865 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 222.0 |
| Day Low | 216.78 |
| Debt To Equity | 44.329 |
| Display Name | Biogen |
| Earnings Call Timestamp End | 1,785,328,200 |
| Earnings Call Timestamp Start | 1,785,328,200 |
| Earnings Growth | -0.848 |
| Earnings Quarterly Growth | -0.846 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | 3,359,200,000 |
| Ebitda Margins | 0.33499 |
| Enterprise To Ebitda | 11.715 |
| Enterprise To Revenue | 3.924 |
| Enterprise Value | 39,354,347,520 |
| Eps Current Year | 12.41218 |
| Eps Forward | 16.53674 |
| Eps Trailing Twelve Months | 5.55 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 207.4136 |
| Fifty Day Average Change | 11.086395 |
| Fifty Day Average Change Percent | 0.053450666 |
| Fifty Two Week Change Percent | 56.484997 |
| Fifty Two Week High | 222.85 |
| Fifty Two Week High Change | -4.350006 |
| Fifty Two Week High Change Percent | -0.019519884 |
| Fifty Two Week Low | 133.53 |
| Fifty Two Week Low Change | 84.97 |
| Fifty Two Week Low Change Percent | 0.63633645 |
| Fifty Two Week Range | 133.53 - 222.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 685,114,200,000 |
| Float Shares | 147,219,129 |
| Forward Eps | 16.53674 |
| Forward P E | 13.213004 |
| Free Cashflow | 1,266,987,520 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 7,500 |
| Fullday Change | -3.0 |
| Fullday Change Percent | -1.3544018 |
| Fullday Price | 218.19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.78322 |
| Gross Profits | 7,854,099,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0018799999 |
| Held Percent Institutions | 0.99514 |
| Implied Shares Outstanding | 147,753,998 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Ir Website | http://www.biogenidec.com/INVESTORS.aspx?ID=5494 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 979,776,000 |
| Last Split Factor | 3:1 |
| Long Business Summary | Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Biogen Inc. |
| Market | us_market |
| Market Cap | 32,284,248,064 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_29726 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 834,600,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 32,727,510,557 |
| Number Of Analyst Opinions | 31 |
| Open | 221.17 |
| Operating Cashflow | 2,878,799,872 |
| Operating Margins | 0.25058 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.56 |
| Phone | 617 679 2000 |
| Post Market Change | -0.30999756 |
| Post Market Change Percent | -0.14187531 |
| Post Market Price | 218.19 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 221.5 |
| Price Eps Current Year | 17.603676 |
| Price Hint | 2 |
| Price To Book | 1.7122482 |
| Price To Sales Trailing12 Months | 3.2194426 |
| Profit Margins | 0.083229996 |
| Quick Ratio | 0.94 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.82857 |
| Region | US |
| Regular Market Change | -3.0 |
| Regular Market Change Percent | -1.3544018 |
| Regular Market Day High | 222.0 |
| Regular Market Day Low | 216.78 |
| Regular Market Day Range | 216.78 - 222.0 |
| Regular Market Open | 221.17 |
| Regular Market Previous Close | 221.5 |
| Regular Market Price | 218.5 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 517,478 |
| Return On Assets | 0.052059997 |
| Return On Equity | 0.04575 |
| Revenue Growth | 0.034 |
| Revenue Per Share | 68.194 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 147,753,998 |
| Shares Percent Shares Out | 0.035099998 |
| Shares Short | 5,190,555 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,999,133 |
| Short Name | Biogen Inc. |
| Short Percent Of Float | 0.0392 |
| Short Ratio | 4.35 |
| Source Interval | 15 |
| State | MA |
| Symbol | BIIB |
| Target High Price | 300.0 |
| Target Low Price | 165.0 |
| Target Mean Price | 236.22 |
| Target Median Price | 237.0 |
| Total Cash | 1,284,999,936 |
| Total Cash Per Share | 8.697 |
| Total Debt | 8,355,100,160 |
| Total Revenue | 10,027,899,904 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 5.55 |
| Trailing P E | 39.36937 |
| Trailing Peg Ratio | 1.5649 |
| Triggerable | 1 |
| Two Hundred Day Average | 189.6331 |
| Two Hundred Day Average Change | 28.866898 |
| Two Hundred Day Average Change Percent | 0.15222499 |
| Type Disp | Equity |
| Volume | 517,478 |
| Website | https://www.biogen.com |
| Zip | 2,142 |